Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Intercept Pharmaceuticals, Inc. ICPT
$15.82
+$0.2 (1.28%)
На 18:00, 12 мая 2023
+38.31%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
656571825.00000000
-
week52high
21.86
-
week52low
10.81
-
Revenue
285710000
-
P/E TTM
6
-
Beta
1.24429000
-
EPS
-4.41000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 12:30
Описание компании
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 22 авг 2022 г. |
| B. Riley Securities | Buy | Buy | 22 авг 2022 г. |
| HC Wainwright & Co. | Neutral | Neutral | 08 авг 2022 г. |
| Raymond James | Outperform | Outperform | 04 авг 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 08 июл 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 03 окт 2022 г. |
| Baird | Outperform | Outperform | 03 окт 2022 г. |
| Raymond James | Outperform | Outperform | 02 ноя 2022 г. |
| HC Wainwright & Co. | Neutral | Neutral | 16 ноя 2022 г. |
| Raymond James | Outperform | Outperform | 20 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Freedberg Jared | D | 58756 | 918 | 01 февр 2023 г. |
| Venezia Rocco | A | 16000 | 16000 | 27 янв 2023 г. |
| Venezia Rocco | A | 25451 | 9800 | 27 янв 2023 г. |
| Berrey M Michelle | A | 24000 | 24000 | 27 янв 2023 г. |
| Berrey M Michelle | A | 83877 | 14700 | 27 янв 2023 г. |
| Durso Jerome Benedict | A | 82700 | 82700 | 27 янв 2023 г. |
| Durso Jerome Benedict | A | 154640 | 50400 | 27 янв 2023 г. |
| Ford David A | A | 16000 | 16000 | 27 янв 2023 г. |
| Ford David A | A | 36438 | 9800 | 27 янв 2023 г. |
| Freedberg Jared | A | 20000 | 20000 | 27 янв 2023 г. |
Новостная лента
Intercept (ICPT) Gains 26.2% YTD: What's in Store?
Zacks Investment Research
12 мая 2023 г. в 12:11
Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA seeking approval of OCA in steatohepatitis (NASH).
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y
Zacks Investment Research
28 апр 2023 г. в 15:12
Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.
Why Intercept Pharmaceuticals Stock Plunged Today
The Motley Fool
27 апр 2023 г. в 15:49
Intercept Pharmaceuticals reported 2023 Q1 earnings today. The company missed Wall Street's revenue estimate for the three-month period by approximately $4.7 million.
Intercept Pharmaceuticals, Inc. (ICPT) Q1 2023 Earnings Call Transcript
Seeking Alpha
27 апр 2023 г. в 14:24
Intercept Pharmaceuticals, Inc. (ICPT) Q1 2023 Earnings Call Transcript.
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
27 апр 2023 г. в 09:53
Intercept Pharmaceuticals (ICPT) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.58 per share a year ago.